Rules on the labeling needs for medtech products entering the Swiss market have been eased in what is seen by the local industry as a victory for pragmatism.
Efforts by the Swiss Medtech industry association to secure less onerous labeling rules for medtech products entering the Swiss market, now that the country’s EU mutual recognition agreement no longer applies, have paid off.
At the end of 2021, the association reached what it describes as a “suitable” agreement with the Federal Office of...
Create an account to read this article
Already a subscriber?
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
The medtech sector in the UK, Switzerland, and Germany face a challenging 2025, heads of national trade groups say. Competition and access to innovation remain key concerns across the board, with collaboration with the EU and US planned in Switzerland while Germany focuses on approaching elections.
Medtechs will be indirectly affected by a new law in Switzerland that unifies the amount of funding allocated to inpatient and ambulatory care.
A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it.
